Association of L55M and Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance

Molecular and Cellular Biochemistry

Volumn 351, Issue 1-2, 2011, Pages 117-123

  Hussein, Yousri M ^a   Gharib, Amal F ^a   Etewa, Rasha L ^a   ElSawy, Wael H ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Breast cancer; Paraoxonase gene polymorphisms

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; DNA;

ADULT; ARTICLE; BLOOD; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DNA DETERMINATION; EGYPT; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MUTANT; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ARYLDIALKYLPHOSPHATASE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EGYPT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 79953709688     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-0718-4     Document Type: Article

References (31)

1. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update. CA Cancer J Clin 56:168-183 (Pubitemid 43847927)
2. Gu D, Wang M (2010) VEGF 936C > T polymorphism and breast cancer risk: evidence from 5,729 cases and 5,868 controls. Breast Cancer Res Treat. doi: 10.1007/s10549-010-0991-z
3. Fattahi MJ, Mojtahedi Z, Karimaghaee N, Talei AR, Ranani SJ, Ghaderi A (2009) Analysis of BRCA1 and BRCA2 mutations in southern Iranian breast cancer patient. Arch Iran Med 12:584-587
4. Delimaris I, Faviou E, Antonakos G, Stathopoulou E, Zachari A, Dionyssiou-Asteriou A (2007) Oxidized LDL, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer. Clin Biochem 40:1129-1134 (Pubitemid 47379323)
5. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160:1-40 (Pubitemid 43227479)
6. Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashor S, Husain SA (2005) Lipid peroxidation, free radical, and antioxidant status in breast cancer. Breast Cancer Res Treat 59:163-170
7. Chander R, Kapoor NK (1990) High-density lipoprotein is a scavenger of superoxide anions. Biochem Pharmacol 40:1663-1665 (Pubitemid 20310588)
8. Mackness B, Durrington PN, Mackness MI (1998) Human serum paraoxonase. Gen Pharmacol 31(3):329-336 (Pubitemid 28398854)
9. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287 (Pubitemid 28335041)
10. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73-76 (Pubitemid 23063292)
11. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE (2001) Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428-1436 (Pubitemid 32510618)
12. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganoy D, Rosenblat M (2000) Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101:2510-2517 (Pubitemid 30366256)
13. Stevens VL, Rodriguez C, Pavluck AL, Thun MJ, Calle EE (2006) Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 15:1226-1228
14. Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, Helzlsouer KJ (2007) Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev 31:95-101 (Pubitemid 46669815)
15. Bloom HI, Richardson WW (1957) Histological grading and prognosis. Br J Cancer 11:359-377
16. Breast. AJCC cancer staging manual (2002) In: American joint committee on cancer. 6th edn. Springer, New York, pp 171-180
17. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y (1997) A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 17:3565-3569 (Pubitemid 28028569)
18. Feigelson HS, Henderson BE (1996) Estrogens and breast cancer. Carcinogenesis 17:2279-2284 (Pubitemid 26402222)
19. Willett Walter C (2000) American association for cancer research diet and cancer: one view at the start of the millennium. Cancer Epidemiol Biomarkers Prev 10:3-8
20. Ambrosone CB (2000) Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2:903-917
21. Gönenç A, Erten D, Aslan S, Akinci M, Simsek B, Torun M (2006) Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int 30:376-380
22. Sener DE, Gonenc A, Akinci M, Torun M (2007) Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem Funct 25:377-382 (Pubitemid 47066711)
23. Tesarová P, Kalousová M, Trnková B, Soukupová J, Argalásová S, Mestek O, Petruzelka L, Zima T (2007) Carbonyl and oxidative stress in patients with breast cancer - is there a relation to the stage of the disease? Neoplasma 54:219-224
24. Tesarová P, Kalousová M, Jáchymová M, Mestek O, Petruzelka L, Zima T (2007) Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 25:720-725 (Pubitemid 350223177)
25. Yu BP (1994) Cellular defenses against damage from reactive oxygen species. Physiol Rev 74:139-162
26. Salama SA, Kamel M, Awad M, Nasser AH, Al-Hendy A, Botting S, Arrastia C (2008) Catecholestrogens induce oxidative stress and malignant transformation in human endometrial glandular cells: protective effect of catechol-O- methyltransferase. Int J Cancer 123:1246-1254
27. Nebert DW, McKinnon RA, Puga A (1996) Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 15:273-280 (Pubitemid 26124084)
28. Antognelli C, Buono CD, Ludovini V, Gori S, Talesa VN, Crino L, Barberini F, Rulli A (2009) CYP17, GSTP1, PON1, and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer 9:115-128
29. Naidu R, Har YC, Taib NAM (2010) Genetic polymorphisms of paraoxonase 1 (PON1) gene: association between L55M or Q192R with breast cancer risk and clinico-pathological parameters. Pathol Oncol Res 16:533-540
30. Brophy VH, Jarvik GP, Richter RJ, Rozek LS, Schellenberg GD, Furlong CE (2000) Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 10:453-460 (Pubitemid 30433578)
31. Ferrè N, Camps J, Fernandez-Ballart J, Arija V, Murphy MM, Ceruelo S, Biarnes E, Vilella E, Tous M, Joven J (2003) Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 49:1491-1497 (Pubitemid 37011737)